COUNTRY EXPLORER / BRAZIL / RESEARCH BRIEF
Brazil
Guaraná, açaí and the difference between a signal and a treatment
Evidence at a glance
A focused botanical research brief, with cancer first and other chronic disease and health questions afterward. Country labels provide geographic context; plants and traditions cross borders, and some studies were conducted elsewhere. This is a selected evidence review, not a national disease-burden survey or a treatment guide.
Cancer
Guaraná and cancer-related fatigue
Human trials · mixed results · supportive care. A 2011 randomized crossover trial in 75 women receiving breast-cancer chemotherapy reported improved fatigue with a standardized guaraná extract. A later study randomized 33 patients after an initial open-label phase and found no significant advantage over placebo on its fatigue measures. Different preparations and small samples make the apparent benefit uncertain.
These studies concern symptoms during cancer care. They do not show that guaraná shrinks tumors, prevents recurrence or extends survival. A phase II study listed by the US National Cancer Institute is examining fatigue in neuroendocrine and early-stage gynecologic cancers; its active status on 23 October 2026 represents an unanswered question, not a positive result. NCI trial listing
Other chronic disease and health
Açaí and metabolic health
Small human studies · no established disease prevention. A 2011 uncontrolled pilot gave açaí pulp to ten overweight adults for one month and found changes in selected glucose, insulin and cholesterol measures. Without a control group, the study cannot separate an açaí effect from other changes over time. Pilot study
A 12-week randomized trial in 37 people with metabolic syndrome found improvements in two inflammatory or oxidative-stress markers, but no significant improvement in glucose or lipid metabolism. Biomarker findings do not establish fewer heart attacks or prevention of diabetes. Randomized trial
Clinical interpretation and safety
Guaraná contains caffeine. Extracts, powders and energy drinks are not interchangeable, and caffeine can contribute to palpitations, anxiety and poor sleep. Review the actual product and other caffeine sources with the clinical team, particularly during cancer treatment. FDA caffeine guidance
What would change the picture? Larger independent fatigue trials with a defined extract and caffeine content; metabolic trials measuring durable clinical outcomes. The studies selected here do not establish either botanical as a cancer treatment.
Research checked: 23 October 2026. Study preparations are described to distinguish the evidence, not to recommend self-treatment. Botanical illustration is interpretive.
